MITO logo

Stealth BioTherapeutics (MITO) Financials

Balance sheets

31 Mar 202231 Dec 202130 Sept 202130 June 202131 Mar 202131 Dec 202030 Sept 202030 June 202031 Mar 2020

Total Assets

$36.9 M(-26.5%)$50.2 M(+13.7%)$44.2 M(+37.0%)$32.3 M(-7.3%)$34.8 M(-3.0%)$35.8 M(+59.1%)$22.5 M(-33.1%)$33.7 M(+4.8%)$32.1 M

Current Assets

$36.4 M(-26.6%)$49.6 M(+14.2%)$43.4 M(+37.4%)$31.6 M(-7.0%)$34.0 M(-3.0%)$35.0 M(+61.8%)$21.7 M(-34.2%)$32.9 M(+3.3%)$31.9 M

Non Current Assets

$515.0 K(-17.5%)$624.0 K(-16.5%)$747.0 K(+15.3%)$648.0 K(-18.4%)$794.0 K(-1.7%)$808.0 K(-7.5%)$873.0 K(+15.0%)$759.0 K(+166.3%)$285.0 K

Total Liabilities

$89.2 M(-6.6%)$95.5 M(+30.8%)$73.0 M(+24.7%)$58.6 M(+25.0%)$46.9 M(+1.4%)$46.2 M(+128.2%)$20.3 M(-8.3%)$22.1 M(-25.7%)$29.7 M

Current Liabilities

$9.9 M(-8.7%)$10.8 M(+12.1%)$9.7 M(-28.0%)$13.4 M(-17.2%)$16.2 M(-23.0%)$21.0 M(+3.9%)$20.3 M(-8.3%)$22.1 M(-25.7%)$29.7 M

Long Term Liabilities

$79.3 M(-6.3%)$84.7 M(+33.7%)$63.4 M(+40.3%)$45.2 M(+47.3%)$30.7 M(+21.8%)$25.2 M(+100.0%)$0.0(0%)$0.0(0%)$0.0

Shareholders Equity

-$52.3 M(-15.5%)-$45.3 M(-57.1%)-$28.8 M(-9.6%)-$26.3 M(-117.9%)-$12.1 M(-16.5%)-$10.4 M(-556.1%)$2.3 M(-80.4%)$11.6 M(+377.3%)$2.4 M

Book Value

-$52.3 M(-15.5%)-$45.3 M(-57.1%)-$28.8 M(-9.6%)-$26.3 M(-117.9%)-$12.1 M(-16.5%)-$10.4 M(-556.1%)$2.3 M(-80.4%)$11.6 M(+377.3%)$2.4 M

Working Capital

$26.5 M(-31.6%)$38.8 M(+14.8%)$33.8 M(+85.7%)$18.2 M(+2.3%)$17.8 M(+27.1%)$14.0 M(+898.6%)$1.4 M(-87.1%)$10.8 M(+405.4%)$2.1 M

Cash And Cash Equivalents

$33.8 M(-28.2%)$47.1 M(+11.5%)$42.3 M(+37.4%)$30.8 M(-4.0%)$32.1 M(-2.2%)$32.8 M(+64.8%)$19.9 M(-37.5%)$31.8 M(+1.9%)$31.2 M

Accounts Payable

$4.1 M(+18.9%)$3.5 M(-11.4%)$3.9 M(+52.6%)$2.6 M(-44.5%)$4.6 M(+31.0%)$3.5 M(+2.1%)$3.5 M(-31.0%)$5.0 M(-23.2%)$6.5 M

Accounts Receivable

---------

Short Term Debt

---$5.5 M(-24.6%)$7.2 M(-19.6%)$9.0 M(+0.2%)$9.0 M(-13.7%)$10.4 M(-28.9%)$14.6 M

Long Term Debt

---------

Total Debt

$0.0(0%)$0.0(0%)$0.0(-100.0%)$5.5 M(-24.6%)$7.2 M(-19.6%)$9.0 M(+0.2%)$9.0 M(-13.7%)$10.4 M(-28.9%)$14.6 M

Debt To Equity

0.0(0%)0.0(0%)0.0(+100.0%)-0.2(+65.0%)-0.6(+31.0%)-0.9(-122.0%)4.0(+338.9%)0.9(-85.1%)6.0

Current Ratio

3.7(-19.6%)4.6(+1.8%)4.5(+90.7%)2.4(+12.4%)2.1(+26.5%)1.7(+55.1%)1.1(-28.2%)1.5(+39.3%)1.1

Quick Ratio

---------

Inventory

---------

Retained Earnings

---------

PB Ratio

-0.8(+26.6%)-1.1(+59.9%)-2.7(+20.2%)-3.4(+52.8%)-7.2(+5.2%)-7.6(-125.8%)29.6(+278.8%)7.8(-57.9%)18.6

Income statements

31 Mar 202231 Dec 202130 Sept 202130 June 202131 Mar 202131 Dec 202030 Sept 202030 June 202031 Mar 2020

EPS

-$0.1(+66.7%)-$0.4(-200.0%)-$0.1(+66.7%)-$0.4(-200.0%)-$0.1(+66.7%)-$0.4(-50.0%)-$0.2(0%)-$0.2(+50.0%)-$0.5

TTM EPS

-$1.0(0%)-$1.0(0%)-$1.0(+11.1%)-$1.1(-12.5%)-$1.0(+27.3%)-$1.3(-83.3%)-$0.7(+25.0%)-$1.0(+20.0%)-$1.2

Revenue

---------

TTM Revenue

---------

Total Expenses

$13.1 M(+2.3%)$12.8 M(+11.7%)$11.4 M(+4.1%)$11.0 M(-0.7%)$11.1 M(+2.3%)$10.8 M(-0.4%)$10.9 M(-8.8%)$11.9 M(-20.6%)$15.0 M

Operating Expenses

$13.1 M(+2.3%)$12.8 M(+11.7%)$11.4 M(+4.1%)$11.0 M(-0.7%)$11.1 M(+2.3%)$10.8 M(-0.4%)$10.9 M(-8.8%)$11.9 M(-20.6%)$15.0 M

Cost Of Goods Sold

---------

TTM Cost Of Goods Sold

---------

Gross Profit

---------

TTM Gross Profit

---------

Gross Margin

---------

Operating Profit

-$13.1 M(-2.3%)-$12.8 M(-11.7%)-$11.4 M(-4.1%)-$11.0 M(+0.7%)-$11.1 M(-2.3%)-$10.8 M(+0.4%)-$10.9 M(+8.8%)-$11.9 M(+20.6%)-$15.0 M

TTM Operating Profit

-$48.3 M(-4.3%)-$46.3 M(-4.4%)-$44.4 M(-1.3%)-$43.8 M(+2.1%)-$44.7 M(+8.1%)-$48.7 M(-44.6%)-$33.7 M(+13.4%)-$38.9 M(+8.3%)-$42.4 M

Operating Margin

---------

Net Income

-$8.1 M(+59.6%)-$20.1 M(-219.8%)-$6.3 M(+65.8%)-$18.4 M(-139.4%)-$7.7 M(+58.1%)-$18.3 M(-63.6%)-$11.2 M(+9.4%)-$12.4 M(+20.4%)-$15.5 M

TTM Net Income

-$53.0 M(-0.8%)-$52.5 M(-3.5%)-$50.7 M(+8.8%)-$55.6 M(-12.2%)-$49.6 M(+13.7%)-$57.5 M(-62.4%)-$35.4 M(+13.1%)-$40.7 M(+7.7%)-$44.1 M

Net Margin

---------

EBIT

-$7.6 M(+61.2%)-$19.6 M(-220.9%)-$6.1 M(+66.5%)-$18.2 M(-146.6%)-$7.4 M(+58.8%)-$18.0 M(-65.0%)-$10.9 M(+8.7%)-$11.9 M(+20.1%)-$14.9 M

TTM EBIT

-$51.5 M(-0.4%)-$51.3 M(-3.3%)-$49.7 M(+8.8%)-$54.4 M(-13.1%)-$48.1 M(+13.5%)-$55.6 M(-67.1%)-$33.3 M(+13.0%)-$38.3 M(+7.7%)-$41.5 M

EBITDA

-$7.6 M(+61.2%)-$19.6 M(-220.9%)-$6.1 M(+66.5%)-$18.2 M(-146.6%)-$7.4 M(+58.7%)-$17.9 M(-65.4%)-$10.8 M(+9.1%)-$11.9 M(+20.1%)-$14.9 M

TTM EBITDA

-$51.5 M(-0.4%)-$51.3 M(-3.4%)-$49.6 M(+8.7%)-$54.3 M(-13.1%)-$48.0 M(+13.5%)-$55.6 M(-67.4%)-$33.2 M(+13.2%)-$38.2 M(+7.7%)-$41.4 M

Selling, General & Administrative Expenses

---------

TTM SG&A

---------

Depreciation And Amortization

---------

TTM D&A

---------

Interest Expense

---------

TTM Interest Expense

---------

Income Tax

---------

TTM Income Tax

---------

PE Ratio

---------

PS Ratio

---------

Cashflow statements

31 Mar 202231 Dec 202130 Sept 202130 June 202131 Mar 202131 Dec 202030 Sept 202030 June 202031 Mar 2020

Cash From Operations

----$23.3 M---$43.8 M(-33.2%)-$32.9 M-

TTM CFO

----$67.1 M---$76.7 M(+11.0%)-$86.2 M-

Cash From Investing

---$245.0 K---$40.0 K(-185.7%)-$14.0 K-

TTM CFI

---$205.0 K---$54.0 K(+62.5%)-$144.0 K-

Cash From Financing

---$21.0 M--$13.0 M(-7.1%)$14.0 M-

TTM CFF

---$34.0 M--$27.0 M(-71.3%)$93.8 M-

Free Cash Flow

----$23.3 M---$43.8 M(-33.2%)-$32.9 M-

TTM FCF

----$67.1 M---$76.8 M(+11.1%)-$86.4 M-

CAPEX

---------

TTM CAPEX

---------

Dividends Paid

---------

TTM Dividends Paid

---------

TTM Dividend Per Share

---------

TTM Dividend Yield

---------

Payout Ratio

---------